Join AlphaMaven

The Home Of Alternative Investments

Register For Free Learn More Create Investment Listing

Most Visited Alternative Investment Industry Website. Over 50,000 visitors per month

Alternative Investment Posts

Andea Alms Video:  Money In Motion 118 - Antibody Drug Conjugate (ADC) Market
Private Equity BrookDell Partners Views: 1

TRANSCRIPT:

Hello, my name is Andrea Alms. I'm a technology investor and financial manager and this is your money in motion. In the news, Merck and company is making a push to dominate small cell lung cancer. In October 2023, Merck paid Daiichi $4 billion to partner on a slate of antibody drug conjugates ADC. Merck paid 800 680 million for Harpic. The original deal between Merck and IHG included a B7, H3 directed ADC that entered phase three.

What is it? Antibody drug conjugates ADCs are mono


Member Posts:

Most popular| Most recent
AlphaMaven Crypto Traders Index
Crypto AlphaMaven Crypto Traders Index #Investment Update
AlphaMaven Cannabis Index
Cannabis AlphaMaven Cannabis Index #Investment Update
AlphaMaven Hedge Fund Index
Hedge Fund AlphaMaven Hedge Fund Index #Investment Update
Alpha Alternative Assets Fund - Fact Sheet
Hedge Fund Alpha Alternative Assets Fund
ParaImbal, LP Investor Presentation - March 2025
Managed Futures Paraimbal #Presentation
Meteora Select Trading Opportunities, LP - AlphaMaven Performance Report
Hedge Fund Meteora Select Trading Opportunities, LP #Investment Update
ParaImbal, LP - AlphaMaven Performance Report
Managed Futures Paraimbal #Investment Update
Rome Capital Long Levered Strategy - AlphaMaven Performance Report
Hedge Fund Rome Capital Long Levered Strategy #Investment Update
Andrea Alms Video:  Money In Motion 153 - FDA Staff Cuts - Biotech Regulatory Delays M ...
Private Equity BrookDell Partners #Video
Andrea Alms Video:  Money In Motion 152 - Tariffs Pharma/Biotech Market Update
Private Equity BrookDell Partners #Video
Andrea Alms Video:  Money In Motion 151 - Ozempic Impact & GLP-1 Receptor Agonist Mark ...
Private Equity BrookDell Partners #Video
Andrea Alms Video:  Money In Motion 150 - Gene Therapy Adeno-Associated Virus (AAV)
Private Equity BrookDell Partners #Video
Andrea Alms Video:  Money In Motion 149 - Pediatric Rare Disease Market
Private Equity BrookDell Partners #Video
Robosig FX Alpha Gen Fund Posts Its March 2025 Results
Hedge Fund RoboSig FX Alpha Gen Fund #Investment Update
ARB Flagship Fund - AlphaMaven Performance Report
Hedge Fund ARB Flagship Fund #Investment Update
SBGM Futures Portfolio Strategy Performance Report
Managed Futures SBGM Futures Portfolio Strategy #Investment Update
AlphaMaven Managed Futures Index
Managed Futures AlphaMaven Managed Futures Index #Investment Update
AlphaMaven Real Estate Index
Real Estate AlphaMaven Real Estate Index #Investment Update
AlphaMaven Private Equity Index
Private Equity AlphaMaven Private Equity Index #Investment Update
AlphaMaven Venture Capital Index
Venture Capital AlphaMaven Venture Capital Index #Investment Update
CREATE A FREE MEMBERSHIP
View Member Posts Listings
SPONSORED BY
Be Seen - Advertise With Us
Click to Discuss
FEATURED MEMBER POSTS
Andrea Alms Video:  Money In Motion 147 - Pediatric Healthcare Market
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 153 - FDA Staff Cuts - Biotech Regulatory Delays Market Update
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 152 - Tariffs Pharma/Biotech Market Update
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 149 - Pediatric Rare Disease Market
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 151 - Ozempic Impact & GLP-1 Receptor Agonist Market Update
- posted by: BrookDell Partners
Andrea Alms Video:  Money In Motion 150 - Gene Therapy Adeno-Associated Virus (AAV)
- posted by: BrookDell Partners
Andrea Alms Video: Money In Motion 148 - Water Market
- posted by: BrookDell Partners
Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates

Subscribe to our FREE DAILY newsletter

Please Select Industry Primary Role*
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
Sign Up Now
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.